Table 6.
Duration of therapy
| Duration of therapy after mahalanobis distance matching | MONARCH 1 N = 108 |
Real-world cohort N = 108 |
Difference/p-value |
|---|---|---|---|
| Number of events, n (%) | 103 (95.4) | 104 (96.3) | |
| Discontinued | 103 (95.4) | 104 (96.3) | |
| Patients censored, n (%) | 5 (4.6) | 4 (3.7) | |
| No documented discontinuation | 5 (4.6) | 4 (3.7) | |
| Minimuma, months | 0.43 | 0.03 | |
| 25th percentile (95% CI) | 1.87 (1.87, 2.24) | 1.45 (0.95, 2.07) | |
| Median (95% CI) | 4.08 (2.79, 5.52) | 2.89 (2.33, 3.98) | |
| 75th percentile (95% CI) | 8.28 (6.02, 11.54) | 6.67 (4.83, 9.99) | |
| Maximum, months | 26.56 + | 26.33 | |
| p-value (2-sided)—log rank unstratified | p = 0.05 | ||
| Hazard ratio (95% CI)—unstratified | 0.764 (0.581, 1.004) |
Quartiles and duration of treatment survival rates, along with 95% CIs were estimated using the Kaplan–Meier method. Corresponding 95% CIs were estimated using the methods of Brookmeyer and Crowley, and Greenwood, respectively
CI Confidence interval, N total number of patients, n number of patients within a specific category
aFor minimum/maximum, ‘ + ’ indicates a censored observation